Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the united states

PharmacoEconomics

Volumn 31, Issue 9, 2013, Pages 823-839

  Villacorta, Reginald ^a   Hay, Joel W ^a   Messali, Andrew ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; USTEKINUMAB;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY ADJUSTED LIFE YEAR; SYSTEMIC THERAPY; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; MODELS, ECONOMIC; PSORIASIS; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; UNITED STATES;

EID: 84883507222     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0078-x     Document Type: Article

References (54)

1. Nestle F, Kaplan D, Barker J. Mechanisms of disease psoriasis. N Engl J Med. 2009;361:496-509.
2. Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-50. (Pubitemid 351509656)
3. Menter A, Korman NJ, Elmets C, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-74.
4. Frankel A, Lebwohl M. Treatment options for psoriasis patients who have failed at least one biological therapy. Adv Psor Inflamm Skin Dis 2010;1(4):119-24.
5. Leonardi C, Kimball A, Papp K, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74. (Pubitemid 351671883)
6. Papp K, Langley R, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84. (Pubitemid 351671884)
7. Griffiths C, Strober B, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010;362:118-28.
8. Miller DW, Feldman SR. Cost-effectiveness of moderate to severe psoriasis treatment. Expert Opin Pharmacother. 2006;7(2):157-67. (Pubitemid 43263255)
9. Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
10. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516-22. (Pubitemid 41400929)
11. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298:221-4. (Pubitemid 47057770)
12. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatol Treat. 2011;22:138-43.
13. Pan F, Brazier N, Shear N, et al. Cost utility analysis based on a head-to-head phase 3 clinical trial comparing ustekinumab and etanercept in patients with moderate to severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14:652-6.
14. Brazier J, Ratcliffe J, Salomon JA, et al., editors. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press; 2007.
15. Report of the Commission on Macroeconomics and Health, Macroeconomics and Health: Investing in Health for Economic Development, World Health Organization. 2001.
16. United States of America, Central Intelligence Agency, The World Factbook. https://www.cia.gov/library/publications/the-world-factbook/geos/us. html. Accessed September 2011.
17. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-66. (Pubitemid 38691110)
18. Gelfand J, Troxel A, Lewis J, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143(12):1493-9. (Pubitemid 350277763)
19. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1-233, i-iv.
20. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;69:3-17. (Pubitemid 39215184)
21. Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004;150:11-23. (Pubitemid 38903574)
22. Pariser DM, et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67(2):245-56.
23. Reich K, et al. An update on long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300-12.
24. Etanercept prescribing indications and medication guide. www.enbrel.com. Accessed July 2011.
25. Ustekinumab prescribing indications and medication guide. www.stelarainfo.com. Accessed July 2011.
26. Schmitt J, Meurer M, Klon M, et al. Assessment of health states utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol. 2008;158:351-9.
27. Currie C, Conway P. Evaluation of the association between EQ5D utility and dermatology life quality index (DLQI) score in patients with psoriasis. Value Health. 2007;10(6):A470-1.
28. Krueger GG, et al. Position paper. Two considerations for patients with psoriasis: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-5. (Pubitemid 30626007)
29. Katugampola R, Lewis V, Finlay A. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945-50. (Pubitemid 46642856)
30. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125-35. (Pubitemid 350298147)
31. Beck J, Kassirer J, Pauker S. A convenient approximation of life expectancy (the "DEALE") I. Validation of the method. Am J Med. 1982;73:883-8. (Pubitemid 13211834)
32. Beck J, Pauker S, Gottlieb J, et al. A convenient approximation of life expectancy (the "DEALE") II. Use in medical decision-making. Am J Med. 1982;73:889-97. (Pubitemid 13211835)
33. Papp K, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12. (Pubitemid 40933433)
34. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35. (Pubitemid 43038667)
35. Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007;156:138-42. (Pubitemid 44924157)
36. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22. (Pubitemid 37448924)
37. Hankin CS, Feldman SR, Szczotka A, Stinger RC, Fish L, Hankin DL. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200-14. (Pubitemid 41202134)
38. Centers for Medicare and Medicaid Services, 2011 Medicare Part B Drug Average Sales Price. http://www.cms.gov/McrPartBDrugAvgSalesPrice/01a18- 2011ASPFiles.asp#TopOfPage. Accessed July 2011.
39. Drugstore.com. http://www.drugstore.com. Accessed July 2011.
40. Centers for Medicare and Medicaid Services, Physician Fee Schedule. https://www.cms.gov/apps/physician-fee-schedule/license-agreement.aspx. Accessed July 2011.
41. National Compensation Survey, All United States, December 2009-January 2011. http://www.bls.gov/ncs/ocs/sp/nctb1476.pdf. Accessed July 2011.
42. Bureau of Labor Statistics, United States Department of Labor. www.bls.gov/data/. Accessed July 2011.
43. Kivitz A, Cohen S, Dowd JE, Edwards W, Thakker S, Wellborne FR, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH Trial. Clin Ther. 2007;28(10):1619-29. (Pubitemid 44838895)
44. Yu A, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429-38.
45. Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20(12):1929-36. (Pubitemid 40179632)
46. Kimball AB, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157-63.
47. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis in health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772-80.
48. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:192-9. (Pubitemid 41779576)
49. Chilton F, et al. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care. 2008;6(1):1-14.
50. Report: US Census Bureau, Statistical Abstract of the United States: 2011. Source: US National Center for Health Statistic. National Vital Statistics Reports, Deaths: Final Data for 2007. Vo. 58, No. 19, May 2010.
51. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-26. (Pubitemid 46955730)
52. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat. 2011;22:65-74.
53. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia A, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603. (Pubitemid 46400183)
54. Ortonne JP, Griffiths CEM, Dauden E, Strohal R, Robertson D, Pederson R, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate to severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol. 2008;3(6):657-65.